Hamed Horati1, Hettie M Janssens1, Camilla Margaroli2, Mieke Veltman3, Marta Stolarczyk4, Matthew B Kilgore2, Jeffrey Chou2, Limin Peng5, Harm A M W Tiddens1, Joshua D Chandler2, Rabindra Tirouvanziam2, Bob J Scholte6. 1. Department of Pediatrics, Division of Respiratory Medicine and Allergology, Erasmus MC-Sophia Children's Hospital, University Hospital Rotterdam, the Netherlands. 2. Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Center for CF and Airways Disease Research, Children's Healthcare of Atlanta, Atlanta, GA, USA. 3. Department of Pediatrics, Division of Respiratory Medicine and Allergology, Erasmus MC-Sophia Children's Hospital, University Hospital Rotterdam, the Netherlands; Department of Cell Biology, Erasmus MC, Rotterdam, the Netherlands. 4. Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. 5. Department of Biostatistics and Bioinformatics, Emory University School of public Health, Atlanta, GA, USA. 6. Department of Pediatrics, Division of Respiratory Medicine and Allergology, Erasmus MC-Sophia Children's Hospital, University Hospital Rotterdam, the Netherlands; Department of Cell Biology, Erasmus MC, Rotterdam, the Netherlands. Electronic address: b.scholte@erasmusmc.nl.
Abstract
BACKGROUND: Previously, we showed that abnormal levels of bioactive lipids in bronchoalveolar lavage fluid (BALF) from infants with cystic fibrosis (CF) correlated with early structural lung damage. METHOD: To extend these studies, BALF bioactive lipid measurement by mass spectrometry and chest computed tomography (CT, combined with the sensitive PRAGMA-CF scoring method) were performed longitudinally at 2-year intervals in a new cohort of CF children (n = 21, aged 1-5 yrs). RESULTS: PRAGMA-CF, neutrophil elastase activity, and myeloperoxidase correlated with BALF lysolipids and isoprostanes, markers of oxidative stress, as well as prostaglandin E2 and combined ceramide precursors (Spearman's Rho > 0.5; P < 0.01 for all). Multiple protein agonists of inflammation and tissue remodeling, measured by Olink protein array, correlated positively (r = 0.44-0.79, p < 0.05) with PRAGMA-CF scores and bioactive lipid levels. Notably, levels of lysolipids, prostaglandin E2 and isoprostanes at first BALF predicted the evolution of PRAGMA-CF scores 2 years later. In wild-type differentiated primary bronchial epithelial cells, and in CFTR-inducible iCFBE cells, treatment with a lysolipid receptor agonist (VPC3114) enhanced shedding of pro-inflammatory and pro-fibrotic proteins. CONCLUSIONS: Together, our findings suggest that bioactive lipids in BALF correlate with and possibly predict structural lung disease in CF children, which supports their use as biomarkers of disease progression and treatment efficacy. Furthermore, our data suggest a causative role of airway lysolipids and oxidative stress in the progression of early CF lung disease, unveiling potential therapeutic targets.
BACKGROUND: Previously, we showed that abnormal levels of bioactive lipids in bronchoalveolar lavage fluid (BALF) from infants with cystic fibrosis (CF) correlated with early structural lung damage. METHOD: To extend these studies, BALF bioactive lipid measurement by mass spectrometry and chest computed tomography (CT, combined with the sensitive PRAGMA-CF scoring method) were performed longitudinally at 2-year intervals in a new cohort of CFchildren (n = 21, aged 1-5 yrs). RESULTS: PRAGMA-CF, neutrophil elastase activity, and myeloperoxidase correlated with BALF lysolipids and isoprostanes, markers of oxidative stress, as well as prostaglandin E2 and combined ceramide precursors (Spearman's Rho > 0.5; P < 0.01 for all). Multiple protein agonists of inflammation and tissue remodeling, measured by Olink protein array, correlated positively (r = 0.44-0.79, p < 0.05) with PRAGMA-CF scores and bioactive lipid levels. Notably, levels of lysolipids, prostaglandin E2 and isoprostanes at first BALF predicted the evolution of PRAGMA-CF scores 2 years later. In wild-type differentiated primary bronchial epithelial cells, and in CFTR-inducible iCFBE cells, treatment with a lysolipid receptor agonist (VPC3114) enhanced shedding of pro-inflammatory and pro-fibrotic proteins. CONCLUSIONS: Together, our findings suggest that bioactive lipids in BALF correlate with and possibly predict structural lung disease in CFchildren, which supports their use as biomarkers of disease progression and treatment efficacy. Furthermore, our data suggest a causative role of airway lysolipids and oxidative stress in the progression of early CFlung disease, unveiling potential therapeutic targets.
Authors: Tim Rosenow; Merel C J Oudraad; Conor P Murray; Lidija Turkovic; Wieying Kuo; Marleen de Bruijne; Sarath C Ranganathan; Harm A W M Tiddens; Stephen M Stick Journal: Am J Respir Crit Care Med Date: 2015-05-15 Impact factor: 21.405
Authors: Dušan Garić; Juan B De Sanctis; Gabriella Wojewodka; Daniel Houle; Shanon Cupri; Asmahan Abu-Arish; John W Hanrahan; Marian Hajduch; Elias Matouk; Danuta Radzioch Journal: J Mol Med (Berl) Date: 2017-07-10 Impact factor: 4.599
Authors: Dušan Garić; Juan B De Sanctis; Juhi Shah; Daciana Catalina Dumut; Danuta Radzioch Journal: Prog Lipid Res Date: 2019-03-12 Impact factor: 16.195
Authors: Shaghayegh Tavakoli Tabazavareh; Aaron Seitz; Peter Jernigan; Carolin Sehl; Simone Keitsch; Stephan Lang; Barbara C Kahl; Michael Edwards; Heike Grassmé; Erich Gulbins; Katrin Anne Becker Journal: Cell Physiol Biochem Date: 2016-05-17
Authors: Guido Veit; Florian Bossard; Julie Goepp; A S Verkman; Luis J V Galietta; John W Hanrahan; Gergely L Lukacs Journal: Mol Biol Cell Date: 2012-09-12 Impact factor: 4.138
Authors: Bradley H Rosen; T Idil Apak Evans; Shashanna R Moll; Jaimie S Gray; Bo Liang; Xingshen Sun; Yulong Zhang; Chandler W Jensen-Cody; Anthony M Swatek; Weihong Zhou; Nan He; Pavana G Rotti; Scott R Tyler; Nicholas W Keiser; Preston J Anderson; Leonard Brooks; Yalan Li; R Marshall Pope; Maheen Rajput; Eric A Hoffman; Kai Wang; J Kirk Harris; Kalpaj R Parekh; Katherine N Gibson-Corley; John F Engelhardt Journal: Am J Respir Crit Care Med Date: 2018-05-15 Impact factor: 30.528